MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Johnson and Johnson

Открыт

СекторЗдравоохранение

153.75 -0.54

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

152.41

Макс.

155.08

Ключевые показатели

By Trading Economics

Доход

3.4B

Продажи

20M

23B

P/E

Средняя по отрасли

17.455

57.333

Прибыль на акцию

2.77

Дивидендная доходность

3.3

Рентабельность продаж

15.235

Сотрудники

138,100

EBITDA

652M

5.9B

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+9.18% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

3.30%

2.63%

Следующий отчет о доходах

16 июл. 2025 г.

Дата следующей выплаты дивидендов

10 июн. 2025 г.

Следующая эксдивидендная дата

27 мая 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

11B

378B

Предыдущая цена открытия

154.29

Предыдущая цена закрытия

153.75

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Johnson and Johnson График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

15 апр. 2025 г., 15:12 UTC

Отчет

J&J Boosts Outlook Despite Incoming Tariff Costs -- Update

15 апр. 2025 г., 10:35 UTC

Главные новости
Отчет

J&J Increases Outlook After Beating 1Q Expectations

18 апр. 2025 г., 11:00 UTC

Главные новости

Johnson & Johnson Pivots Its AI Strategy -- WSJ

17 апр. 2025 г., 20:34 UTC

Отчет

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

17 апр. 2025 г., 18:24 UTC

Отчет

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

15 апр. 2025 г., 19:06 UTC

Отчет

These Stocks Are Moving the Most Today: Bank of America, Citigroup, Netflix, Boeing, Tesla, HPE, Applied Digital, and More -- Barrons.com

15 апр. 2025 г., 18:52 UTC

Обсуждения рынка
Отчет

J&J's 1Q Performance Signals Positive Outlook for MedTech Sector -- Market Talk

15 апр. 2025 г., 14:54 UTC

Отчет

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15 апр. 2025 г., 13:19 UTC

Отчет
Приобретения, слияния, поглощения

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15 апр. 2025 г., 11:52 UTC

Отчет

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15 апр. 2025 г., 11:14 UTC

Отчет

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15 апр. 2025 г., 10:51 UTC

Отчет

These Stocks Are Moving the Most Today: Boeing, Tesla, Bank of America, J&J, Netflix, Allegro MicroSystems, and More -- Barrons.com

15 апр. 2025 г., 10:37 UTC

Главные новости
Отчет

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Rises. -- Barrons.com

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson Now Sees 2025 Operational Sales of $91.6B-$92.4B Vs. Prior Outlook $90.9B-$91.7B >JNJ

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson Backs 2025 Adj EPS $10.50-Adj EPS $10.70 >JNJ

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson Raises 2025 View To Sales $91B-$91.8B Vs Prior View $89.2B-$90B >JNJ

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.50-$10.70 Vs Prior View $10.75-$10.95 >JNJ

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson: Including Tariff Costs, Dilution From Intra-Cellular Therapies Buy and Updated Forex, Maintain FY Adj EPS Outlook of 6.2% Growth at Mid-Point >JNJ

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson: Strong 1Q Operational Sales Growth Reinforces Our Confidence in 2025 Guidance >JNJ

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 1Q Sales $21.89B >JNJ

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson: Increasing FY25 Operational Sales Guidance to Reflect Addition of Caplyta Following Completion of Intra-Cellular Therapies Acquisition >JNJ

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 1Q Worldwide MedTech Sales $8.02B >JNJ

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 1Q International Sales $9.59B >JNJ

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 1Q Adj EPS $2.77 >JNJ

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 1Q Orthopaedics Sales $2.24B >JNJ

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson: MedTech 1Q Operational Sales Growth Driven Primarily by Abiomed and Wound Closure Products, Partially Offset by Spine, Sports & Other >JNJ

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson Still Sees 2025 Adjusted Operational Sales Growth of 2.0%-3.0% >JNJ

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson: Innovative Medicine 1Q Sales Growth Driven in Part by Higher Sales of Darzalex and Spravato, Partially Offset by Falling Sales of Stelara >JNJ

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 1Q U.S. Sales $12.31B >JNJ

15 апр. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 1Q EPS $4.54 >JNJ

Сравнение c конкурентами

Изменение цены

Johnson and Johnson Прогноз

Целевая цена

By TipRanks

9.18% рост

Прогноз на 12 месяцев

Средняя 169.15 USD  9.18%

Максимум 185 USD

Минимум 159 USD

Основано на мнении 14 аналитиков Wall Street, спрогнозировавших целевые цены для Johnson and Johnson  на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

14 ratings

7

Покупка

7

Удержание

0

Продажа

Техническая оценка

By Trading Central

154.36 / 157.47Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

Bearish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.